Julie Agopian

Voir les publications Voir le mail Tel : +33 (0)4 86 97 72 84

Equipe

Signalisation, Hématopoïèse et Mécanismes de l’Oncogenèse

May 2014 Haematologica

SRSF2-p95 hotspot mutation is highly associated with advanced forms of mastocytosis and mutations in epigenetic regulator genes.

Hanssens K, Brenet F, Agopian J, Georgin-Lavialle S, Damaj G, Cabaret L, Chandesris MO, de Sepulveda P, Hermine O, Dubreuil P, Soucie E

Feb 2017 Lancet (London, England)

Masitinib for treatment of severely symptomatic indolent systemic mastocytosis: a randomised, placebo-controlled, phase 3 study.

Lortholary O, Chandesris MO, Bulai Livideanu C, Paul C, Guillet G, Jassem E, Niedoszytko M, Barete S, Verstovsek S, Grattan C, Damaj G, Canioni D, Fraitag S, Lhermitte L, Georgin Lavialle S, Frenzel L, Afrin LB, Hanssens K, Agopian J, Gaillard R, Kinet JP, Auclair C, Mansfield C, Moussy A, Dubreuil P, Hermine O

Dec 2015 Biomedical papers of the Medical Faculty of the University Palacky, Olomouc, Czechoslovakia

Rapid and clinically significant response to masitinib in the treatment of mucosal primary esophageal melanoma with somatic KIT exon 11 mutation involving brain metastases: A case report.

Prosvicova J, Lukesova S, Kopecky J, Grim J, Papik Z, Kolarova R, Navratilova B, Dubreuil P, Agopian J, Mansfield C, Moussy A, Hermine O

Voir toutes les publications